Epizyme Inc.

NASDAQ: EPZMHealthcare / Biotechnology / USA
15.12+0.1500+1.00%Vol 1 666 6521Y Perf 2.22%
Jun 24th, 2019 16:00
BID15.05 ASK15.68
Open15.00 Previous Close14.97
Pre-Market- After-Trading15.06
 - -%  -0.06 -0.40%
Target Price
17.75 
Analyst Rating
Strong Buy 1.22
Potencial %
17.39 
Finscreener Ranking
★★★★★ —    -
Insiders Trans % 3/6/12M
-/-/100 
Value Ranking
 —    -
Insiders Value % 3/6/12M
-/-/100 
Growth Ranking
★★★+     54.79
Insiders Shares Cnt. % 3/6/12M
-/-/100 
Income Ranking
 —    -
Market Cap (mil)1 373 
Earnings Rating
Strong Buy
Price Range Ratio 52wk %
87.16 
Earnings Date
1st Aug 2019

Today's Price Range

14.9116.59

52wk Range

5.1416.59

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Month
16.94%
3 Months
30.34%
6 Months
182.09%
1 Year
2.22%
3 Years
53.50%
5 Years
-46.52%

Name / TickerPriceChg.Chg.%
EPZM15.120.15001.00
AAPL198.58-0.2000-0.10
GOOG1 115.52-6.3600-0.57
MSFT137.780.81000.59
XOM76.95-0.7400-0.95
WFC46.27-0.6200-1.32
JNJ143.060.97000.68
FB192.601.46000.76
GE10.28-0.2000-1.91
JPM108.66-0.7800-0.71
Earnings HistoryEstimateReportedSurprise %
Q01 2019-0.47-0.3917.02
Q04 2018-0.49-0.2940.82
Q03 2018-0.60-0.5410.00
Q02 2018-0.53-0.4220.75
Q01 2018-0.54-0.499.26
Q04 2017-0.56-0.527.14
Q03 2017-0.65-0.633.08
Q02 2017-0.56-0.4814.29
Earnings Per EndEstimateRevision %Trend
6/2019 QR-0.533.64Positive
9/2019 QR-0.474.08Positive
12/2019 FY-2.008.26Positive
12/2020 FY-1.797.73Positive
Next Report Date1st Aug 2019
Estimated EPS Next Report-0.53
Estimates Count8
EPS Growth Next 5 Years %-
Volume Overview
Volume1 666 652
Shares Outstanding (in ths.)90 833
Trades Count7 343
Dollar Volume21 999 169
Avg. Volume884 638
Avg. Weekly Volume1 273 487
Avg. Monthly Volume1 039 102
Avg. Quarterly Volume795 319
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
8 (88.89 %)
8 (88.89 %)
8 (88.89 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (11.11 %)
1 (11.11 %)
1 (11.11 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
RatingStrong Buy
1.22
Strong Buy
1.22
Strong Buy
1.22

Epizyme Inc.

Epizyme Inc is a clinical-stage biopharmaceutical company that is committed to rewriting treatment for cancer and other serious diseases through discovering, developing & commercializing novel epigenetic medicines. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL), Phase II clinical trial for relapsed or refractory patients with mesothelioma, Phase I dose-escalation and expansion study for children with INI1-negative solid tumors. The company is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias & PRMT5 inhibitor.

CEO: Robert B. Bazemore

Teplephone: +1 617 229-5872

Address: 400 Technology Square, Cambridge 02139, MA, USA

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

44%56%

Bearish Bullish

61%39%

Bearish Bullish

67%33%

News